Clinical and Biological Characterization of Patients and Collection of Samples (THE-RNA)
Primary Purpose
Tricho Hepato Enteric Syndrome
Status
Not yet recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Blood sample
Fecal samples
Neuropsychological
Sponsored by
About this trial
This is an interventional diagnostic trial for Tricho Hepato Enteric Syndrome
Eligibility Criteria
Inclusion Criteria:
- patient < 18 year-old
- patients with SD/THE
control group :
- patients with tufting enteropathy and short bowel syndrome.
Exclusion Criteria:
- child among whom the parents or the legal representatives refused that their child participates in this study
Sites / Locations
- Assistance Publique Hopitaux de Marseille
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
patients with SD/THE
control group
Arm Description
Outcomes
Primary Outcome Measures
Assessment of detailed clinical characteristics of the phenotype of Tricho-hepato-enteric syndrome
Existence or absence of 9 clinical signs suggestive of Tricho-hepato-enteric syndrome, to know:
neonatal characteristics,
existence or not of the 9 clinical signs suggestive of the disease,
initial symptoms and chronology leading to the diagnosis,
organ damage,
nutrition,
treatment,
growth,
dermatological evaluation,
hepatic evaluation,
neuropsychological evaluation (score of WPPSI-III, WISC-IV, WAIS-IV),
quality of life scale (VSPA in children between 3 and 17 years old and WHOQUOL in adults),
self-report anxiety scale (STAI in children over 8 years)
Secondary Outcome Measures
Full Information
NCT ID
NCT04499040
First Posted
August 31, 2016
Last Updated
July 30, 2020
Sponsor
Assistance Publique Hopitaux De Marseille
1. Study Identification
Unique Protocol Identification Number
NCT04499040
Brief Title
Clinical and Biological Characterization of Patients and Collection of Samples
Acronym
THE-RNA
Official Title
Tricho-hepato-enteric Syndrome: From Abnormal RNA Decay to Disease Clinical and Biological Characterization of Patients and Collection of Samples -THE-RNA
Study Type
Interventional
2. Study Status
Record Verification Date
July 2020
Overall Recruitment Status
Not yet recruiting
Study Start Date
September 1, 2020 (Anticipated)
Primary Completion Date
August 31, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique Hopitaux De Marseille
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Objectives: Collect clinical and biological data about patients with SD/THE, collect samples of patients; create a secure on line database to collect worldwide data about SD/THE Partners : APHM, HCL, APHP
Currently10 patients (8 with TTC37 mutations and 2 with SKIV2l mutations) present a SD/THE and are managed in France in 5 different centers (Marseille, Paris Trousseau, Paris Necker, Paris Robert Debrés, and Lyon). Most of them are followed in hepato-gastro-enterology units for their intractable diarrhea. Three aspects of the disease: intractable diarrhea, immune defect and liver disease are responsible for the main part of the burden of the disease .For each aspect, the investigators will propose a close follow-up with collection of clinical, biochemical, functional and microbial data.
Collect of clinical date: during a programmed consultation clinical data about symptom will be collected twice a year. A detailed form will be used for better delineation of the symptoms. These data included growth, symptom (diarrhea, pain …), and clinical signs. Most of these children have recurrent sample for follow up. During them some blood will be take for study the immune side but also the platelet function.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tricho Hepato Enteric Syndrome
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
patients with SD/THE
Arm Type
Experimental
Arm Title
control group
Arm Type
Placebo Comparator
Intervention Type
Biological
Intervention Name(s)
Blood sample
Intervention Description
Blood samples to assess biological parameters such as:
Intervention Type
Other
Intervention Name(s)
Fecal samples
Intervention Description
Microbiota analysis
Intervention Type
Behavioral
Intervention Name(s)
Neuropsychological
Intervention Description
Neuropsychological assessment
Primary Outcome Measure Information:
Title
Assessment of detailed clinical characteristics of the phenotype of Tricho-hepato-enteric syndrome
Description
Existence or absence of 9 clinical signs suggestive of Tricho-hepato-enteric syndrome, to know:
neonatal characteristics,
existence or not of the 9 clinical signs suggestive of the disease,
initial symptoms and chronology leading to the diagnosis,
organ damage,
nutrition,
treatment,
growth,
dermatological evaluation,
hepatic evaluation,
neuropsychological evaluation (score of WPPSI-III, WISC-IV, WAIS-IV),
quality of life scale (VSPA in children between 3 and 17 years old and WHOQUOL in adults),
self-report anxiety scale (STAI in children over 8 years)
Time Frame
3 years
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
patient < 18 year-old
patients with SD/THE
control group :
patients with tufting enteropathy and short bowel syndrome.
Exclusion Criteria:
child among whom the parents or the legal representatives refused that their child participates in this study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alexandre FABRE
Phone
491382747
Ext
+33
Email
alexandre.fabre@ap-hm.fr
First Name & Middle Initial & Last Name or Official Title & Degree
DRS AP-HM, Sponsor
Phone
491382747
Ext
+33
Email
drci@ap-hm.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jean-Olivier Arnaud
Organizational Affiliation
Assistance Publique Hopitaux De Marseille
Official's Role
Study Director
Facility Information:
Facility Name
Assistance Publique Hopitaux de Marseille
City
Marseille
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
ALEXANDRE FABRE
Email
alexandre.fabre@ap-hm.fr
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Clinical and Biological Characterization of Patients and Collection of Samples
We'll reach out to this number within 24 hrs